Double maintains 2 strategies that include AXSM - Axsome Therapeutics, Inc.
Current Value
$113.081 Year Return
Current Value
$113.081 Year Return
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XPH | 47.56% | $155.51M | 0.35% |
| XBI | 41.57% | $5.19B | 0.35% |
| PBE | 41.33% | $233.59M | 0.58% |
| IBB | 40.37% | $5.59B | 0.45% |
| IHE | 38.22% | $562.06M | 0.39% |
| BBH | 38.01% | $345.62M | 0.35% |
| PINK | 37.34% | $132.39M | 0.5% |
| PTH | 36.63% | $97.64M | 0.6% |
| VHT | 36.56% | $15.49B | 0.09% |
| FBT | 36.10% | $1.05B | 0.54% |
| FHLC | 36.00% | $2.46B | 0.084% |
| IXJ | 35.38% | $3.80B | 0.41% |
| QUS | 35.27% | $1.57B | 0.15% |
| INCM | 34.83% | $724.51M | 0.38% |
| USMV | 34.82% | $23.69B | 0.15% |
| OUSA | 34.64% | $822.18M | 0.48% |
| IYH | 34.61% | $2.76B | 0.39% |
| SCYB | 34.50% | $1.20B | 0.03% |
| TDVG | 34.44% | $887.56M | 0.5% |
| DLN | 34.43% | $5.12B | 0.28% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CRNX | 41.06% | $3.09B | -39.01% | 0.00% |
| XENE | 36.83% | $2.50B | -22.20% | 0.00% |
| ACHV | 35.52% | $136.63M | -44.44% | 0.00% |
| IONS | 35.52% | $6.77B | -10.55% | 0.00% |
| ALNY | 35.18% | $41.17B | +23.25% | 0.00% |
| MIRM | 34.36% | $2.64B | +34.95% | 0.00% |
| MNDY | 33.91% | $14.77B | +22.99% | 0.00% |
| SDGR | 33.58% | $1.55B | -6.83% | 0.00% |
| ALIT | 33.20% | $2.98B | -23.27% | 1.40% |
| COGT | 33.15% | $1.55B | +19.89% | 0.00% |
| ABEO | 32.89% | $302.85M | +9.83% | 0.00% |
| ARGX | 32.84% | $34.35B | +21.51% | 0.00% |
| ARWR | 32.79% | $2.57B | -35.52% | 0.00% |
| XNCR | 32.35% | $629.86M | -55.03% | 0.00% |
| DNLI | 32.27% | $2.13B | -37.03% | 0.00% |
| HON | 31.93% | $153.00B | +10.36% | 1.89% |
| NRIX | 31.87% | $970.14M | -44.05% | 0.00% |
| RVMD | 31.76% | $7.15B | -16.59% | 0.00% |
| ZYME | 31.63% | $937.88M | +29.99% | 0.00% |
| DNTH | 31.34% | $644.16M | -30.93% | 0.00% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| VSA | -11.36% | $12.16M | +21.20% | 0.00% |
| ZCMD | -10.41% | $28.79M | -11.91% | 0.00% |
| AIFU | -9.09% | $17.40M | +87.81% | 0.00% |
| EVGO | -8.56% | $470.93M | -12.47% | 0.00% |
| SHLS | -7.04% | $961.26M | -15.44% | 0.00% |
| LITB | -6.75% | $25.36M | -69.22% | 0.00% |
| CMTL | -5.27% | $76.13M | -20.80% | 0.00% |
| CYCN | -5.06% | $10.59M | +13.01% | 0.00% |
| FSLR | -4.95% | $17.25B | -24.64% | 0.00% |
| WBA | -4.84% | $9.96B | -1.62% | 4.34% |
| CNC | -4.67% | $15.25B | -53.58% | 0.00% |
| PLRX | -4.05% | $89.01M | -89.04% | 0.00% |
| TRUG | -3.62% | $5.16M | -90.45% | 0.00% |
| K | -3.14% | $27.64B | +41.46% | 2.87% |
| PLUG | -2.98% | $1.80B | -51.09% | 0.00% |
| OLLI | -2.69% | $7.87B | +23.96% | 0.00% |
| MOH | -2.34% | $11.87B | -22.90% | 0.00% |
| NEXA | -2.22% | $662.20M | -33.51% | 0.00% |
| CME | -2.19% | $99.84B | +44.13% | 1.75% |
| SRRK | -2.08% | $3.66B | +319.00% | 0.00% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| MMIN | 0.03% | $321.61M | 0.3% |
| KMLM | 0.44% | $186.86M | 0.9% |
| AGZ | 0.67% | $610.98M | 0.2% |
| BSCP | -0.72% | $3.25B | 0.1% |
| TBLL | -0.82% | $2.12B | 0.08% |
| IBTF | 0.86% | $1.98B | 0.07% |
| SMMU | 0.89% | $898.04M | 0.35% |
| STOT | -1.05% | $254.22M | 0.45% |
| IBTG | 1.25% | $1.93B | 0.07% |
| GSST | -1.28% | $925.21M | 0.16% |
| UDN | -1.46% | $147.26M | 0.78% |
| JMST | -1.48% | $4.09B | 0.18% |
| SMB | -1.57% | $276.89M | 0.07% |
| ITM | 1.73% | $1.87B | 0.18% |
| SPSK | 1.76% | $326.14M | 0.5% |
| CGSM | -1.82% | $725.21M | 0.25% |
| USDU | -1.85% | $129.88M | 0.5% |
| SPTS | -1.93% | $5.78B | 0.03% |
| IBDQ | -2.19% | $2.96B | 0.1% |
| UUP | 2.28% | $183.22M | 0.77% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| UFI | 0.04% | $88.68M | -16.00% | 0.00% |
| MNSO | 0.10% | $5.53B | -3.45% | 3.29% |
| HUSA | -0.11% | $20.46M | -9.15% | 0.00% |
| QXO | -0.11% | $14.11B | -60.25% | 0.00% |
| PRA | -0.20% | $1.22B | +103.25% | 0.00% |
| NGL | -0.21% | $563.70M | -9.15% | 0.00% |
| THS | -0.21% | $1.04B | -45.41% | 0.00% |
| MKTX | 0.24% | $8.15B | -1.09% | 1.39% |
| VHC | -0.28% | $74.47M | +193.32% | 0.00% |
| STG | 0.33% | $56.15M | +27.66% | 0.00% |
| NEUE | 0.36% | $60.89M | +31.91% | 0.00% |
| JRVR | 0.40% | $253.33M | -33.57% | 1.44% |
| CMP | -0.41% | $917.73M | +92.91% | 0.00% |
| RILY | 0.42% | $138.46M | -72.77% | 0.00% |
| ERIE | 0.44% | $16.15B | -7.40% | 1.55% |
| SYPR | 0.48% | $47.57M | +11.87% | 0.00% |
| FRPT | 0.50% | $3.51B | -44.08% | 0.00% |
| RUM | -0.55% | $3.00B | +23.57% | 0.00% |
| LCID | -0.61% | $6.92B | -37.12% | 0.00% |
| ANF | 0.69% | $4.39B | -44.96% | 0.00% |
Yahoo
NEW YORK, July 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the second quarter of 2025 on Monday, August 4, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. To participate
Yahoo
NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will host its Frontiers in Brain Health R&D Day on July 21, 2025, starting at 11:00 a.m. Eastern Time in New York City. The event will highlight Axsome’s singular, innovative late-stage CNS pipeline. At the event, physician key opinion leaders will discuss the company’s current indic
Yahoo
Axsome Therapeutics, Inc. (NASDAQ:AXSM) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On July 3, Morgan Stanley analyst Sean Laaman assumed coverage of Axsome Therapeutics, Inc. (NASDAQ:AXSM) with an Overweight rating and a $190 price target. The firm stated that the base case for the rating is the expected […]
Yahoo
HRMY isn't your typical cannabis play - its synthetic CBD gel targets rare brain disorders with no approved therapies.
Yahoo
Axsome Therapeutics Inc. (NASDAQ:AXSM) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. Piper Sandler analysts maintained their $148 price target for Axsome Therapeutics Inc. (NASDAQ:AXSM) and reaffirmed their Overweight rating on June 10. This decision comes after the company revealed that the FDA had sent it a […]
Yahoo
NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today is joining with the Alzheimer’s disease advocacy community to raise awareness of the growing impact of Alzheimer’s disease in the United States and the importance of brain health during this year’s Alzheimer’s & Brain Awareness Month. “Alzheimer’s & Brain Awareness Month offers the perfect opportunity
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| VIXY | -25.97% | $200.94M | 0.85% |
| TAIL | -25.84% | $94.90M | 0.59% |
| VIXM | -21.27% | $22.99M | 0.85% |
| BTAL | -20.50% | $310.24M | 1.43% |
| GBIL | -13.39% | $6.37B | 0.12% |
| ULST | -11.17% | $592.71M | 0.2% |
| CLIP | -10.51% | $1.51B | 0.07% |
| BOXX | -9.93% | $6.97B | 0.19% |
| XHLF | -9.53% | $1.73B | 0.03% |
| SGOV | -7.10% | $50.94B | 0.09% |
| SHV | -6.88% | $20.75B | 0.15% |
| XBIL | -6.84% | $781.34M | 0.15% |
| PSQA | -6.73% | $36.50M | 0.2% |
| IVOL | -6.57% | $341.06M | 1.02% |
| BILS | -5.92% | $3.80B | 0.1356% |
| FXE | -5.26% | $592.85M | 0.4% |
| BIL | -4.96% | $41.78B | 0.1356% |
| USFR | -4.77% | $18.61B | 0.15% |
| BILZ | -4.03% | $852.10M | 0.14% |
| TPMN | -3.64% | $30.86M | 0.65% |
